News

WHAT'S NEW

Fri, October 5, 2018

Baidy Industries, Inc. has acquired NanoAl LLC, a world leader in the science of nanocrystalline strengthening technology applied to sheet aluminum, as a third wholly-owned subsidiary. NanoAl will join the Braidy Atlas aluminum rolling mill and Veloxint in the Braidy Industries company portfolio of holdings.NanoAl was founded out of the Department of Materials Science at Northwestern University to commercialize the science of developing stronger aluminum alloys through control of key structural features at the nanoscale. Braidy believes the technology has the potential to significantly enhance the specific strength of aluminum to be produced by its Braidy Atlas mill, creating a competitive advantage within the automotive and aerospace OEM marketplace.
 
Dr. Nhon Q. Vo, Chief Executive, Chief Technology Officer and Co-Founder of NanoAl said, “Our new partnership with Braidy Industries and Veloxint provides the opportunity to scale our research and development capabilities and become the innovation leader in nano-science technology of light metals.” Craig T. Bouchard, Braidy Industries Chairman and Chief Executive said, “We have been pleasantly surprised at the opportunity to grow our powder metallurgy business via acquisition."

 

Thu, September 20, 2018

Approximately $11.2 million in subsequent financing led by Luye Pharma Group and others including Eager Info Investments LTD, Knoll Capital Management and Purple Arch Ventures . With this investment, the company has raised a total of approximately $31.5 million in this current round.

"Nucleic acid therapeutics hold great promise because they target the underlying genetic source of disease," said Dr. David Giljohann, Chief Executive Officer of Exicure. "Toxicity and delivery have been the primary challenges for companies seeking to use nucleic acids in drug development. Our SNA technology seeks to overcome these challenges and to change the cost curves and development timelines of highly targeted medicines. We are advancing a pipeline of drugs for a broad range of chronic conditions and orphan diseases in dermatology, ophthalmology, respiratory and gastric disorders, and solid tumors. We welcome this new round of investors in Exicure as they bring great insight into rapidly emerging markets for our products."

"As we look to the next generation of innovative pharmaceuticals, we clearly see a major role for nucleic acid therapies that regulate genes and enhance the immune system to combat disease," said Dr. Li You Xin, Senior Vice President and head of R&D of Luye Pharma Group. "The team at Exicure has made tremendous strides in unlocking the potential of these highly-targeted medicines.
"

 

Tue, September 4, 2018

Honoring the lifesaving work of blood collection professionals.  September 2-8, 2018. This milestone honors the lifesaving work and contributions of blood collectors. These professionals each day serve as the vital link between blood donors and patients who count on blood transfusions for a multitude of serious medical conditions including cancer, organ transplants or following an accident or other trauma.

“This week, we herald the immense skill, dedication and care with which blood collectors bring to making blood, an essential therapy, safe and readily available to the many patients who rely on transfusions each day,” said Dean Gregory, president, medical devices at Fresenius Kabi USA. “We’re pleased to partner again with AABB to recognize the many blood collection professionals in the U.S. who play an important role in saving patients’ lives.”